<DOC>
	<DOCNO>NCT02136836</DOCNO>
	<brief_summary>The objective study investigate proportion HER2 overexpression gastric cancer patient group , evaluate relation HER2 overexpression prognosis , analyze proportion herceptin apply patient clinical field . Furthermore , investigator go reevaluate clinical benefit Herceptin survival prolongation compare chemotherapy .</brief_summary>
	<brief_title>Investigation Proportion Human Epidermal Growth Factor Receptor 2 Protein Overexpression Gastric Adenocarcinoma Prognostic Effect HER2 , Analysis Practice Pattern Herceptin Use Stage IV Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Histologically confirm gastric adenocarcinoma 2 . Patients diagnose 20062013 3 . HER2 expression status evaluate primary gastric cancer metastatic lesion . Patients second primary cancer within 5 year</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Genes , erbB-2</keyword>
	<keyword>Prognosis</keyword>
</DOC>